The drug is approved to treat CD19+ acute lymphoblastic leukemia (ALL), and Philadelphia chromosome-positive B-cell precursor ALL that has relapsed or is refractory to treatment, A meta-analysis [97] of 18 studies involving 1373 patients treated with blinatumomab has shown a complete remission (CR) rate of 54% (95%CI: 44–64%). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.